Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Claudia Sommer, MD

University of Würzburg, Würzburg, Germany

9:35 MIN

CIDP

Learn about clinical studies for the treatment of CIDP with immunoglobulin.

DOWNLOAD PDF

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

15:31 MIN

CIDP

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

DOWNLOAD PDF

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements

Jeffrey A. Allen, MD

University of Minnesota

12:15 MIN

CIDP

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

DOWNLOAD PDF

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

12:13 MIN

CIDP

Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients

DOWNLOAD PDF

NOW PLAYING

9:35

Clinical Studies for the Treatment of CIDP with Immunoglobulin

Learn about clinical studies for the treatment of CIDP with immunoglobulin.

NOW PLAYING

15:31

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

NOW PLAYING

12:15

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength...

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

NOW PLAYING

12:13

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabiliza...

Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients

Our Experts on CIDP

VIEW ALL EXPERTS

Thomas Harbo, MD, PhD

Aarhus University Hospital in Aarhus, Denmark

Thomas Harbo, MD, PhD

Aarhus University Hospital in Aarhus, Denmark

CIDP
GBS

Dr. Harbo is a neuromuscular specialist at Aarhus University Hospital in Aarhus, Denmark, a certified Centre of Excellence by the GBS|CIDP Foundation International.

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

CIDP
GBS
MMN

Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.

Carol L. Koski, MD

GBS/CIDP Foundation International

Carol L. Koski, MD

GBS/CIDP Foundation International

CIDP
GBS

Dr. Koski is a retired Professor of Neurology from the University of Maryland School of Medicine and is currently a Director of the GBS/CIDP Foundation International.

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring